Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
about
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.Solid phase synthesis of nucleobase and ribose modified inosine nucleoside analogues.Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic culturesUse of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia virusesSynthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors.Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virusPolymeric nanogel formulations of nucleoside analogs.Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelSerine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activityOrthopoxvirus targets for the development of new antiviral agents.The design and development of drugs acting against the smallpox virus.Historical perspectives in the development of antiviral agents against poxvirusesAnalgesic, Antibacterial and Antiviral Activities of 2-(5-Alkyl-1,3,4-oxadiazol-2-yl)-3H-benzo[f]chromen-3-ones.Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus.Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.Molecular structure differences between the antiviral Nucleoside Analogue 5-iodo-2'-deoxyuridine and the natural nucleoside 2'-deoxythymidine using MP2 and DFT methods: conformational analysis, crystal simulations, DNA pairs and possible behaviour.FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.Inhibitory efficacy of cyclosal-nucleoside monophosphates of aciclovir and brivudin on DNA synthesis of orthopoxvi ruses.A guided tour through the antiviral drug field
P2860
Q30231576-B9D1CF34-636E-46DC-8974-4AD44E4003D0Q33309300-2EA93225-8522-44FF-B27E-866D049FBA20Q34196187-06078BDA-B19B-4B14-973A-180CE6527D7BQ34721564-FA65E4F4-598B-42B3-88E8-344E4D334DE5Q35023470-EA42B6FA-4DEA-4E21-8CA2-BFD2776061D1Q35046606-12162758-9962-40EE-AA90-DE4451D1ECD2Q35215440-1E324870-BEA4-4C9E-8648-8452273AA55BQ35784850-453A5A48-D28C-470E-A5DA-962A1EAB2A35Q36499021-3984A010-1591-4E6C-AE8E-1C9DA18D4838Q36668023-8F5F0F31-5DF0-4CD5-ADF8-AF83191314C3Q36734750-80AF5254-E4DA-4609-A4E5-D2EF994FCC80Q37069884-4F62A8CA-B8D5-4C11-8F3D-923B5BA19703Q37173398-7E97A800-AF92-4E2E-9359-FB54C470EF94Q38089868-B75ECD1B-7FAB-4544-A05D-570A4EFB1160Q38617932-A9A4350B-6387-4625-A72E-EB078A13CF4EQ39955805-70147B02-3794-4F6A-9709-35BDA3CF806FQ40358241-5BECC56A-C712-45A7-B9CC-39A6B6904C80Q41343033-EFCF4C09-C618-4CEA-A789-ED05E919D817Q41361126-987C7A00-4C07-4D2C-8676-EA2586B86C35Q44554964-FAE9458E-0E5E-465D-90C9-81D3B8DA4A23Q50734762-93B5ECEF-4722-42DA-9B21-72764E0DF03DQ54613400-0FA83A88-F61F-452C-8E19-A33DD6749F17Q56786373-550F49CF-A416-487E-95DB-A30BDB8C1A7A
P2860
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@ast
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@en
type
label
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@ast
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@en
prefLabel
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@ast
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@en
P356
P1476
Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections.
@en
P304
P356
10.1002/RMV.439
P577
2004-09-01T00:00:00Z